Health Economics Review

Papers
(The H4-Index of Health Economics Review is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
The healthcare costs of increased body mass index–evidence from The Trøndelag Health Study103
Contracting with sequential care providers56
The cost of implementing measles campaign in Nigeria: comparing the stand-alone and the integrated strategy52
Building an integrated healthcare system of China: an assessment of coupling coordination between disease prevention, medical services, and healthcare financing from 2012 to 202145
A cost-effectiveness analysis comparing single-inhaler extrafine beclomethasone/formoterol/glycopyrronium bromide against other SITTs in adult patients with uncontrolled asthma in England43
End-of-life expenditure on health care for the older population: a scoping review30
Evaluating a capacity development intervention in health economics among producers and users of evidence in Nigeria: a case study in Getting Research Into Policy and Practice (GRIPP) in Anambra State29
Governance and public health expenditure in Côte d'Ivoire: examination of the dynamic relationship28
Which factor reduces pharmaceutical expenditure, number of entrants or price variance? Updated generic drug markets in South Korea27
Valuation of informal care for the old-aged with disabilities in China—a discrete choice experiment approach25
Utilization of maternal health facilities and rural women’s well-being: towards the attainment of sustainable development goals23
Evaluating the costs of adverse drug events in hospitalized patients: a systematic review22
Adjuvant treatment of high-risk melanoma – cost-effectiveness analysis of treatment options for BRAF 600 mutated tumors21
Impact of diabetes diagnosis on dental care utilization: evidence from Finland21
Health insurance coverage in Ethiopia: financial protection in the Era of sustainable development goals (SDGs)20
Correction: Health state utility values for metastatic pancreatic cancer using a composite time trade-off based on the vignette-based approach in Japan18
The economic impact of anastomotic leak after colorectal cancer surgery17
Cost-utility analysis of valsartan, enalapril, and candesartan in patients with heart failure in Iran17
Policies and cost analyses of voluntary assisted dying (VAD) laws – a mapping review & analysis17
Support by telestroke networks is associated with increased intravenous thrombolysis and reduced hospital transfers: A german claims data analysis17
Estimating the budget impact of a Tuberculosis strategic purchasing pilot study in Medan, Indonesia (2018–2019)17
0.087363958358765